Evidence map›Paper›PMID 41039162›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Autophagy-Targeting Fe-Cu Nanozyme for Tumor Immune Microenvironment Remodeling and Image-Guided Cancer Immunotherapy.

Li Yan, Chao Chen, Yu Liang, Xiaowan Huang, Jieying Qian, Hao Zhang, Li Zhang, Yingjia Li, Yunjiao Zhang

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Li YanDepartment of Medicine Ultrasonics, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, P. R. China.
Chao ChenSchool of Medicine, South China University of Technology, Guangzhou, 510006, P. R. China.
Yu LiangDepartment of Medicine Ultrasonics, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, P. R. China.
Xiaowan HuangSchool of Medicine, South China University of Technology, Guangzhou, 510006, P. R. China.
Jieying QianSchool of Medicine, South China University of Technology, Guangzhou, 510006, P. R. China.
Hao ZhangSchool of Medicine, South China University of Technology, Guangzhou, 510006, P. R. China.
Li ZhangDepartment of Medicine Ultrasonics, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, P. R. China.
Yingjia LiDepartment of Medicine Ultrasonics, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, P. R. China.
Yunjiao ZhangSchool of Medicine, South China University of Technology, Guangzhou, 510006, P. R. China.ORCID https://orcid.org/0000-0002-6465-7488

Funding

Basic and Applied Basic Research of Guangzhou 2024A04J5851Guangzhou Municipal Science and Technology Project 2023B03J1350National Key R&D Program of China 2024YFA0918600National Key R&D Program of China 2024YFA1212100National Natural Science Foundation of China 32571631National Natural Science Foundation of China 82102081National Natural Science Foundation of China 82202155National Natural Science Foundation of China 82271998National Natural Science Foundation of China 82402452National Natural Science Foundation of China 82572394National Natural Science Foundation of China T2222014Natural Science Foundation for Outstanding Youth Team Project of Guangdong Province 2024B1515040030
6 · The paper itself

Abstract

The suppressive tumor immune microenvironment (TIME) is a critical driver of tumor progression, immune evasion, and therapy resistance. Despite the transformative potential of immunotherapy, autophagy within the TIME weakens immune surveillance by downregulating tumor cell surface major histocompatibility complex class I (MHC-I) expression, thereby facilitating immune escape. Here, a novel nanozyme-based strategy is reported to modulate autophagy and restore anti-tumor immunity. Iron-copper metal-organic frameworks (Fe-Cu MOFs) are engineered with tunable peroxidase, glutathione peroxidase, and oxidase-like activities, and an optimal Fe:Cu ratio that confers potent redox activity alongside robust inhibition of autophagic flux is identified. These MOF nanozymes selectively impair autophagy and restore MHC-I expression in tumor cells, enhancing immune recognition. To further potentiate autophagic blockade, a multifunctional nanoplatform (FCMP@CQ/PFH) is developed by co-loading low-dose chloroquine (CQ) and encapsulating perfluorohexane (PFH) into the Fe-Cu MOFs. This combinatorial system couples nanozyme-driven redox stress with lysosomal inhibition to synergistically suppress autophagy and reinvigorate anti-tumor immune responses. Moreover, PFH facilitates ultrasound-based real-time visualization of therapeutic efficacy. Both in vitro and in vivo studies show that FCMP@CQ/PFH enhances cancer immunotherapy and suppresses metastasis. This study establishes a dual-functional approach that combines autophagy inhibition with immune microenvironment reprogramming to circumvent immune resistance and advance precision cancer immunotherapy.

Indexed as

AutophagyCopperImmunotherapyIronNeoplasmsTumor MicroenvironmentAnimalsCell Line, TumorHumansMetal-Organic FrameworksMiceCopperIronMetal-Organic Frameworksautophagy inhibitioncancer immunotherapymetal–organic frameworksnanoenzymeultrasound imaging

Identifiers

PMID41039162
PMCPMC12713008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.